LOS ANGELES–(BUSINESS WIRE) – Schall law firm, a national shareholder rights law firm, announces that it is investigating securities violations claims on behalf of investors of Tricida, Inc. ("Tricida" or "the Company") (NASDAQ: TCDA).
The investigation focuses on whether the company has made false and / or misleading statements and / or has failed to disclose information that is relevant to investors. Tricida announced in a July 15, 2020 press release that the FDA had notified the company of its new drug application (“NDA”) for drug candidate veverimer (TRC101). The FDA notification states that the agency has "ha (d) identified deficiencies that preclude discussion of labeling and post-marketing requirements / obligations at this point". Based on the news, Tricida shares fell 40% the next day.
If you are a shareholder who has suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335 to discuss your rights at no charge. You can also contact us on the company's website at www.schallfirm.com or by email at firstname.lastname@example.org.
Schall law firm represents investors around the world and specializes in class action and shareholder disputes.
This press release may be viewed as a solicitor advertisement in some jurisdictions under applicable laws and ethical rules.